

Special Issue

Lung Cancer Proteogenomics: New Era, New Insights

Message from the Guest Editor

Lung cancer remains a major public health concern, constituting the second most prevalent malignancy and the leading cause of cancer-related mortality worldwide. Lung cancer incidence and outcomes vary depending on factors such as age, sex, ethnicity, smoking habits, environment, and socioeconomic status. Integration of high-throughput molecular data originating from mass spectrometry (proteomics) to those of next-generation sequencing (genomics, transcriptomics) are currently paving the way towards designating molecular causes of cancer tumorigenesis. Proteogenomics is increasingly becoming a valuable instrument for biomedical research. For this Special Issue, we invite authors to contribute original research articles, as well as review articles that address recent achievements in proteogenomics associated with lung cancer research. Potential topics include but are not limited to the following:

- Methods of genomic, transcriptomic, and proteomic data integration;
- Bioinformatic tools towards metagenomics and metaproteomics;
- Clinical lung cancer proteogenomics towards precision medicine;
- Lung cancer multi-omics.

Guest Editor

Dr. Thanasis Anagnostopoulos

Division of Biotechnology, Center of Systems Biology, Biomedical Research Foundation of the Academy of Athens (BRFAA), 11525 Athens, Greece

Deadline for manuscript submissions

closed (15 July 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/145680

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)